Tanespimycin
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].
Product Specifications
CAS Number
75747-14-7
Product Name Alternative
17-AAG; NSC 330507; CP 127374
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/17-AAG.html
Purity
99.01
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
Molecular Formula
C31H43N3O8
Molecular Weight
585.69
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
HSP90
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (B-K9), CF568 conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF405S conjugate, 0.1mg/mL
Cytokeratin 17 (E3), CF405S conjugate, 0.1mg/mL
